866-997-4948(US-Canada Toll Free)

Osteosarcoma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Oct 2013

Category :

Oncology

No. of Pages : 60 Pages


Global Markets Directs, \'Osteosarcoma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Osteosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteosarcoma. Osteosarcoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Osteosarcoma.
  • A review of the Osteosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Osteosarcoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Osteosarcoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Osteosarcoma Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Osteosarcoma 8
Osteosarcoma Therapeutics under Development by Companies 10
Osteosarcoma Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Osteosarcoma Therapeutics - Products under Development by Companies 16
Osteosarcoma Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Osteosarcoma Therapeutics Development 18
Shionogi & Co., Ltd. 18
Merck & Co., Inc. 19
Oncolytics Biotech Inc. 20
Med Discovery SA 21
Aileron Therapeutics, Inc. 22
Hawthorn Pharmaceuticals, Inc. 23
Eleison Pharmaceuticals, Inc. 24
Osteosarcoma - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
cisplatin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MDRG-01 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
pelareorep - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
robatumumab - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Angiotensin 1-7 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
sirolimus + [cyclophosphamide] - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
HU14.18K322A - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PBF Peptide Vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Haw mAb-11 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Dendritic Cell Vaccine + [decitabine] + [imiquimod] - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
p53 Transcription Factor Derived Stapled Peptides - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
MBC-11 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Drugs Targeting Thymidylate Synthase And Dihydrofolate Reductase - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
De-Methylated Derivatives Of Colchicine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Peptide Cocktail Vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Osteosarcoma Therapeutics - Drug Profile Updates 50
Osteosarcoma Therapeutics - Discontinued Products 55
Osteosarcoma Therapeutics - Dormant Products 56
Osteosarcoma - Product Development Milestones 57
Featured News & Press Releases 57
Jun 24, 2011: PCI Biotech Announces Main Results Of Full Phase I/II Study Of Amphinex 57
Apr 27, 2011: Oncolytics Biotech Announces Start Of Conformity Testing With SAFC 57
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014 58

Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Table


Number of Products Under Development for Osteosarcoma, H2 2013 8
Products under Development for Osteosarcoma - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Clinical Stage Development, H2 2013 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Shionogi & Co., Ltd., H2 2013 18
Merck & Co., Inc., H2 2013 19
Oncolytics Biotech Inc., H2 2013 20
Med Discovery SA, H2 2013 21
Aileron Therapeutics, Inc., H2 2013 22
Hawthorn Pharmaceuticals, Inc., H2 2013 23
Eleison Pharmaceuticals, Inc., H2 2013 24
Assessment by Monotherapy Products, H2 2013 25
Assessment by Combination Products, H2 2013 26
Assessment by Stage and Route of Administration, H2 2013 28
Assessment by Stage and Molecule Type, H2 2013 30
Osteosarcoma Therapeutics - Drug Profile Updates 50
Osteosarcoma Therapeutics - Discontinued Products 55
Osteosarcoma Therapeutics - Dormant Products 56

List of Chart


Number of Products under Development for Osteosarcoma, H2 2013 8
Products under Development for Osteosarcoma - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 12
Mid Clinical Stage Products, H2 2013 13
Early Clinical Stage Products, H2 2013 14
Discovery and Pre-Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 25
Assessment by Combination Products, H2 2013 26
Assessment by Route of Administration, H2 2013 27
Assessment by Stage and Route of Administration, H2 2013 28
Assessment by Molecule Type, H2 2013 29
Assessment by Stage and Molecule Type, H2 2013 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *